ChemioCare is a pharmaceutical company working on a proprietary transdermal delivery platform.
Focused on improving quality of life and outcomes for patients undergoing cancer treatment, we believe that there is a significant opportunity to improve the profiles of generic medicines included in the standard of care by using transdermal technology.
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
